Company intelligence / Profile preview
Fate Therapeutics
San Diego, California, USAfatetherapeutics.com ↗
- Ownership
- Public · FATE
- Development stage
- Phase 1
01
Overview
Fate Therapeutics has reported promising early clinical data from its Phase I trials. For example:
FT819, an off-the-shelf iPSC-derived CAR T-cell therapy targeting CD19 for moderate-to-severe SLE, received FDA Regenerative Medicine Advanced Therapy designation based on initial safety and activity data showing potential efficacy without intensive conditioning chemotherapy[6][4].
FT522, a CD19-targeted CAR NK cell product incorporating Alloimmune Defense Receptor technology designed to reduce need for conditioning chemotherapy, showed persistence and anti-B cell activity through Day15 in relapsed/refractory B-cell lymphoma patients[4][9].
The company is actively expanding dose levels and indications while presenting translational data at major scientific meetings[9].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Induced pluripotent stem cell (iPSC)-derived cellular therapiesOff-the-shelf CAR T-cell therapiesCAR NK cell therapiesGenetically engineered immune cells
- Industry
- Biotech
02
Drug pipeline
32 assets31 more assets in the full pipeline.
03
Partnerships
Ono Pharmaceutical – collaboration for development/commercialization of solid tumor program FT825/ONO8250 in US/EU markets[8]. Additional research collaborations with academic centers are ongoing but not specifically named[3].
04
Financials
- Market cap
- $215.6M
- Total revenue
- $6.6M
- Enterprise value
- $151M
Beyond the preview
Go deeper on Fate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fate Therapeutics.